奥浦迈发行股份及支付现金购买澎立生物100%股权事项 修订审核问询函回复并提示交易尚需审批

Core Viewpoint - The company Aopumai (688293.SH) announced plans to acquire 100% equity of Chengli Biopharmaceutical Technology (Shanghai) Co., Ltd. through a combination of share issuance and cash payment, with the transaction still subject to multiple approval processes, leading to uncertainty regarding its final implementation [1][2]. Group 1 - The company has completed the revision of its response to the inquiry letter from the Shanghai Stock Exchange regarding the transaction [1]. - The asset evaluation of Chengli Biopharmaceutical's identifiable net assets has been completed, prompting the company to supplement and revise parts of its response based on further feedback from the exchange [1]. - The revised response documents have been published on the Shanghai Stock Exchange's website [1]. Group 2 - The implementation of the transaction is contingent upon several prerequisites, including approval from the Shanghai Stock Exchange and registration consent from the China Securities Regulatory Commission [2]. - The company has emphasized the uncertainty surrounding the approval and registration timeline for the transaction [2]. - The company will adhere to legal and regulatory requirements for timely information disclosure based on the transaction's progress [2].